Identification of Main Factors Explaining Glucose Dynamics During and Immediately After Moderate Exercise in Patients With Type 1 Diabetes

Journal of Diabetes Science and Technology

Volumn 9, Issue 6, 2015, Pages 1185-1191

  Brahim, Najib Ben ^a   Place, Jerome ^a   Renard, Eric ^a   Breton, Marc D ^a  

^a INSERM   (France)

Author keywords

artificial pancreas; exercise; hypoglycemia; physical activity; T1DM

Indexed keywords

ANTIDIABETIC AGENT; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; INSULIN;

ADOLESCENT; ADULT; ALGORITHM; ARTIFICIAL PANCREAS; BIOLOGICAL MODEL; BLOOD; DIABETES MELLITUS, TYPE 1; DRUG EFFECTS; EQUIPMENT DESIGN; EXERCISE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; META ANALYSIS; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICAL MODEL; TIME FACTOR;

ADOLESCENT; ADULT; ALGORITHMS; BIOMARKERS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; EQUIPMENT DESIGN; EXERCISE; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LINEAR MODELS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PANCREAS, ARTIFICIAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS;

EID: 85016924051     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/1932296815607864     Document Type: Article

References (41)

1. American Diabetes Association. Physical activity/exercise and diabetes. Diabetes Care. 2004;27:S58-S62.
2. Lehmann R, Kaplan V, Bingisser R, Bloch K, and Spinas G. Impact of physical activity on cardiovascular risk factors in IDDM. Diabetes Care. 1997;20:1603-1611.
3. De Feo P, Fatone C, Mazzeschi C, Battistini D. Endocrinology of Physical Activity and Sport. 2nd ed. Constantini N, Hackney AC, eds. New York, NY: Springer; 2013, pp. 501-511.
4. Brazeau AS, Rabasa-Lhoret R, Strychar I, Mircescu H. Barriers to physical activity among patients with type 1 diabe-tes. Diabetes Care. 2008;31:2108-2109.
5. McMahon SK, Ferreira LD, Ratnam N, et al. Glucose require-ments to maintain euglycemia after moderate-intensity after-noon exercise in adolescents with type 1 diabetes are increased in a biphasic manner. J Clin Endocrinol Metab. 2007;92: 963-968.
6. Brown RJ, Wijewickrama RC, Harlan DM, Rother KI. Uncoupling intensive insulin therapy from weight gain and hypoglycemia in type 1 diabetes. Diabetes Technol Ther. 2011;13:457-460.
7. Dose Adjustment for Normal Eating Study Group. Training in flexible, intensive insulin management to enable dietary free-dom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE). BMJ. 2002;325:746-751.
8. Cobelli C, Renard E, Kovatchev B. Artificial pancreas: past, present, future. Diabetes. 2011;60:2672-2682.
9. Steil GM, Rebrin K, Darwin C, Hariri F, Saad MF. Feasibility of automating insulin delivery for the treatment of type 1 dia-betes. Diabetes. 2006;55:3344-3350.
10. Zisser H, Renard E, Kovatchev B, et al. Multicenter closed-loop insulin delivery study points to challenges for keep-ing blood glucose in a safe range by a control algorithm in adults and adolescents with type 1 diabetes from various sites. Diabetes Technol Ther. 2014;8:8.
11. Kovatchev BP, Renard E, Cobelli C, et al. Safety of outpatient closed-loop control: first randomized crossover trials of a wearable artificial pancreas. Diabetes Care. 2014;37: 1789-1796.
12. Finan DA, McCann TW Jr, Rhein K, et al. Effect of algorithm aggressiveness on the performance of the Hypoglycemia-Hyperglycemia Minimizer (HHM) system. J Diabetes Sci Technol. 2014;8:685-690.
13. Doyle FJ III, Huyett LM, Lee JB, Zisser HC, Dassau E. Closed-loop artificial pancreas systems: engineering the algorithms. Diabetes Care. 2014;37:1191-1197.
14. Nimri R, Muller I, Atlas E, et al. Night glucose control with MD-Logic artificial pancreas in home setting: a single blind, randomized crossover trial-interim analysis. Pediatr Diabetes. 2014;15:91-99.
15. Kovatchev BP, Renard E, Cobelli C, et al. Safety of outpatient closed-loop control: first randomized crossover trials of a wearable artificial pancreas. Diabetes Care. 2014;37: 1789-1796.
16. Phillip M, Battelino T, Atlas E, et al. Nocturnal glucose control with an artificial pancreas at a diabetes camp. N Engl J Med. 2013;368:824-833.
17. Borg G, Noble BJ: Perceived exertion. In: Wilmore J, ed. Exercise and Sport Science Reviews. New York, NY: Academic Press; 1974:131-154.
18. Russell SJ, El-Khatib FH, Sinha M, et al. Outpatient glycemic control with a bionic pancreas in type 1 diabetes. N Engl J Med. 2014;371:313-325.
19. El-Khatib FH, Russell SJ, Magyar KL, et al. Autonomous and continuous adaptation of a bihormonal bionic pancreas in adults and adolescents with type 1 diabetes. J Clin Endocrinol Metab. 2014;99:1701-1711.
20. Damiano ER, El-Khatib FH, Zheng H, Nathan DM, Russell SJ. A comparative effectiveness analysis of three continuous glucose monitors. Diabetes Care. 2013;36:251-259.
21. Russell SJ, El-Khatib FH, Nathan DM, Magyar KL, Jiang J, Damiano ER. Blood glucose control in type 1 diabetes with a bihormonal bionic endocrine pancreas. Diabetes Care. 2012;35:2148-2155.
22. Ward WK, Castle JR, El Youssef J. Safe glycemic management during closed-loop treatment of type 1 diabetes: the role of glucagon, use of multiple sensors, and compensation for stress hyperglycemia. J Diabetes Sci Technol. 2011;5: 1373-1380.
23. Haidar A, Legault L, Dallaire M, et al. Glucose-responsive insulin and glucagon delivery (dual-hormone artificial pan-creas) in adults with type 1 diabetes: a randomized crossover controlled trial. CMAJ. 2013;185:297-305.
24. Rizza RA, Mandarino LJ, Gerich JE. Effects of growth hormone on insulin action in man: mechanisms of insulin resistance, impaired suppression of glucose production, and impaired stimulation of glucose utilization. Diabetes. 1982;31:663-669.
25. Hansen I, Tsalikian E, Beaufrere B, Gerich J, Haymond M, Rizza R. Insulin resistance in acromegaly: defects in both hepatic and extrahepatic insulin action. Am J Physiol. 1986;250:E269-E273.
26. Breton MD, Brown SA, Karvetski CH, et al. Adding heart rate signal to a control-to-range artificial pancreas system improves the protection against hypoglycemia during exercise in type 1 diabetes. Diabetes Technol Ther. 2014;16:506-511.
27. Turksoy K, Quinn L, Littlejohn E, Cinar A. Multivariable adaptive identification and control for artificial pancreas sys-tems. IEEE Trans Biomed Eng. 2014;61:883-891.
28. Stenerson M, Cameron F, Payne SR, et al. The impact of accel-erometer use in exercise-associated hypoglycemia prevention in type 1 diabetes [published online ahead of print September 17, 2014]. J Diabetes Sci Technol.
29. Gallen I. Helping the athlete with type 1 diabetes. Br J Diabetes Vasc Dis. 2004;4:87-92.
30. Hastie T, Tibshirani R, Friedman J. The Elements of Statistical Learning. New York, NY: Springer; 2001.
31. Akaike H. A new look at the statistical model identification. IEEE Trans Autom Control. 1974;19:716-723.
32. Akaike H. Fitting autoregressive models for prediction. Ann Inst Stat Math. 1969;21:1.
33. Weinzimer SA, Sherr J, Cengiz E, et al. Reduction of post-prandial glucose excursions during closed-loop (CL) feedback controlled insulin delivery with a manual priming bolus: 029. Pediatr Diabetes. 2006;7(suppl):67-68.
34. Parker RS, Doyle FJ III, Peppas NA. A model-based algorithm for blood glucose control in type 1 diabetic patients. IEEE Trans Biomed Eng. 1999;46:148-157.
35. Hovorka R, Canonico V, Chassin LJ, et al. Nonlinear model predictive control of glucose concentration in subjects with type 1 diabetes. Physiol Meas. 2004;25:905-920.
36. Cobelli C, Man CD, Sparacino G, et al. Diabetes: models, sig-nals, and control. IEEE Rev Biomed Eng. 2009;2:54-96.
37. Schmidt S, Boiroux D, Dunn-Henriksen AK, et al. Model-based closed-loop glucose control in type 1 diabetes: the DiaCon experience. J Diabetes Sci Technol. 2013;7: 1255-1264.
38. Mauseth R, Wang Y, Dassau E, et al. Proposed clinical application for tuning fuzzy logic controller of artificial pancreas utilizing a personalization factor. J Diabetes Sci Technol. 2010;4:913-922.
39. Mauseth R, Hirsch IB, Bollyky J, et al. Use of a “fuzzy logic” controller in a closed-loop artificial pancreas. Diabetes Technol Ther. 2013;15:628-633.
40. Clarke WL, Anderson S, Breton M, et al. Closed-loop artificial pancreas using subcutaneous glucose sensing and insulin delivery and a model predictive control algorithm: the Virginia experience. J Diabetes Sci Technol. 2009;3:1031-1038.
41. Hughes CS, Patek SD, Breton MD, Kovatchev BP. Hypoglycemia prevention via pump attenuation and red-yel-low-green “traffic” lights using continuous glucose monitoring and insulin pump data. J Diabetes Sci Technol. 2010;4: 1146-1155.